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A high prevalence of hepatitis C virus infection in por-
phyria cutanea tarda in some populations suggests a
close link between viral hepatitis and alteration of por-
phyrin metabolism. Moreover, there is evidence of a
role of porphyrinopathies in hepatocarcinogenesis.
The aim of our study was to obtain data on the preva-
lence and patterns of heme metabolism alterations in
patients with chronic hepatitis C virus infection. Uri-
nary porphyrin excretion was prospectively studied in
100 consecutive outpatients with chronic hepatitis C
infection without signs of photosensitivity, using an
ion-pair high-performance liquid chromatography
method. Increased total porphyrin excretion was
found in 41 patients, with predominant excretion of
coproporphyrins (whole study group: mean 146 µg/g
creatinine, interquartile range 76–186; normal < 150),
in 10 patients excretion exceeded 300 µg/g creatinine.
In the majority of all patients studied (75/100) an in-
creased ratio of the relatively hydrophobic copropor-
phyrin isomer I to isomer III was found. In just one case,
urinary porphyrin pattern characteristic for chronic he-
patic porphyria was present (uroporphyrin > copropor-
phyrin, heptacarboxyporphyrin III increased) but the
total porphyrin excretion was only slightly elevated in
this case. In the whole group, total urinary porphyrin
excretion correlated well with serum bilirubin and was
inversely correlated with albumin and thrombin time.
In conclusion, secondary coproporphyrinuria occurs
frequently in heptatitis C infection, whereas in Ger-
many, preclinical porphyria cutanea tarda seems to be
rare in these patients.
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Introduction
The identification of chronic viral hepatitis C as a fre-
quent coexisting disease in porphyria cutanea tarda
(PCT) with an increasing gradient from northern to
southern Europe (1–4) suggests association between
viral hepatitis and porphyrinopathies. Increased uri-
nary porphyrin excretion has been recognised for
many years in various hepatobiliary diseases (5, 6).
Whereas PCT, in which uroporphyrin and heptacar-
boxyporphyrin excretion are largely elevated (7),
causes characteristic dermatological symptoms, the
mere excess of urinary coproporphyrins is generally
considered to be a biological indicator not related to
any symptoms.
There is growing evidence to suspect that chronic
disturbance of heme metabolism may be involved in
hepatocarcinogenesis (8, 9): a high risk for hepatocellu-
lar carcinoma has been recognised in patients with
chronic hepatic porphyria and cirrhosis (10, 11). In
acute intermittent porphyria an increased risk of cirrho-
sis and hepatocellular carcinoma (HCC) has been dem-
onstrated (12–14); a case of HCC associated with the
rare hereditary coproporphyria has been described
(15). Massively elevated levels of urinary coproporphy-
rin have been found in patients with HCC compared to
patients with liver diseases without HCC (16). Several
cases of PCT related to benign or malignant hepatocel-
lular tumors have been reported (17, 18). Besides these
epidemiological observations, there are important ex-
perimental data indicating a role of altered porphyrin
metabolism in hepatocarcinogenesis: toxic com-
pounds that induce HCC (such as polyhalogenated bi-
phenyls or ketoconazole in animal models) usually ex-
hibit potent porphyrinogeneic properties (19–23).
Based on these findings we decided to reevaluate
possible pathophysiological and prognostic signifi-
cance of secondary porphyrinuria in liver diseases, and
especially in chronic hepatitis C infection with its high
rate of progression to cirrhosis and finally HCC (24).
Only few systematic studies on urinary porphyrin ex-
cretion, with conflicting results, have been performed
in well defined groups of patients with liver diseases (5,
6, 25–29); therefore, links between abnormal porphyrin
metabolism, disease progression to cirrhosis and he-
patocarcinogenesis in heptatitis C are so far unclear. In
order to obtain basic epidemiological data on urinary
porphyrin excretion in liver diseases for further study
on prognostic implications we studied urine porphyrin
excretion patterns in patients with chronic HCV infec-
tion. One hundred consecutive HCV patients were in-
cluded in the study to answer three main questions:
(i) What is the prevalence of increased urinary por-
phyrin excretion in patients with HCV infection?
(ii) What patterns of the main porphyrin compounds
(coproporphyrin isomers I and III, uroporphyrin I and
III) are found; to what extent can the pattern typical for
chronic hepatic porphyria (i.e. markedly increased uro-
porphyrin excretion) as “preclinical” PCT be found?
(iii) Is there any association of porphyrin excretion
patterns with routine laboratory tests of liver cell integ-
rity, function or biliary excretion, that characterise the
stage of liver disease?
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Patients and Methods
One hundred consecutive patients with serologically
confirmed hepatitis C infection (HCV-RNA positive, ele-
vated ALT) attending the hepatology outpatients’ ser-
vice were included in the study. In all cases, the reason
for the patients’ presentation was an evaluation for a po-
tential therapy with interferon. Forty-eight patients were
female, 52 male, the median age was 47 years 
(range 22–78). After informed consent, patients were
interviewed for dermatological abnormalities and the
sun exposed skin was examined. Patients with signifi-
cant (> 20 g per day) alcohol consumption were not in-
cluded. A random sample of urine was collected from
each patient and immediately protected from light; the
urine was stored at –20 °C until analysis. No additional
blood sampling was performed for this study. The re-
sults of clinically indicated routine laboratory serum
tests, and hematological and coagulation laboratory
tests (determined on the day of urine collection) were 
recorded (bilirubin, AST, ALT, g-glutamyltransferase
(GGT), alkaline phosphatase (AP), albumin, ferritin,
transferrin saturation calculated from serum transferrin
and iron, and thrombin time); mechanised standard clin-
ical chemistry methods run on autoanalyzers were used
(Roche Diagnostics, Mannheim, Germany). Data on vi-
ral load (HCV-RNA quantification, by HCV-Amplicor
monitor®, Roche Diagnostics) were recorded as well.
Patients were stratified into three groups according
to the total porphyrin excretion: group I had porphyrin
excretion within the normal range (< 150 µg/g creati-
nine); group II had porphyrin excretion up to twice the
reference range (150–300 µg/g creatinine); group III had
porphyrin excretion more than twice the reference
range (> 300 µg/g creatinine).
In addition, urinary porphyrin excretion patterns
were studied in 18 patients with cholestasis due to bile
duct obstruction.
Urinary porphyrin analysis
An ion-pair high-performance liquid chromatographic
(HPLC) method was used as described previously (30);
this method is routinely performed in our institution.
Sample preparation
Six ml of urine was oxidised with 0.3 ml of a solution
containing 5 g I2 and 10 g Kl in 100 ml water for 5 min, to
convert quantitatively porphyrinogens into the corre-
sponding porphyrins. Excess iodine was removed with
Na2S2O3, and subsequently 6 ml 1.2 mol/l H3PO4 were
added. The porphyrins were adsorbed on SepPak C18
cartridges (Waters, Milford MA, USA) and eluted with 5
ml of methanol/acetone (1+1, by volume). The solvents
were removed under vacuum, and the residue was dis-
solved in 1.9 ml of 50 mmol/l methanolic tetrabutylam-
monium phosphate; as internal standard, 100 µl of 4
µmol/l mesoporphyrin (Sigma, Deisenhofen, Ger-
many) in 50 mmol/l methanolic tetrabutylammonium
phosphate was added. After centrifugation, 50 µl of this
solution was injected for HPLC analysis.
HPLC conditions
Precolumn: LiChrospher 4x4 RP18 5 µm (Merck, Darm-
stadt, Germany). Analytical column: LiChrospher
125x4 RP18 5 µm (Merck). Mobile phase: multilinear
gradient starting with 62 % aqueous phosphate buffer
(40 mmol/l, pH 5.4) and 38 % methanolic phase (12.5
mmol/l tetrabutylammonium phosphate, pH 7.2). Final
composition after 40 min: 20 % aqueous phase and 
80 % methanolic phase. Fluorescence detection: excita-
tion wavelength 395 nm, emission wavelength 625 nm.
The interassay coefficient of variation (n = 11) of this
method is 4 % to 7 % depending on the respective por-
phyrin compound. The recovery rate varies between 
95 % and 97 %.
Uroporphyrin I and III, coproporphyrin I and III, and
heptacarboxyporphyrin III concentrations were calcu-
lated in relation to the respective urinary creatinine
concentration and the total urinary porphyrin excretion
was determined by summing up the concentrations of
these analytes. Normally, less than 150 µg porphyrin
per g creatinine are excreted (< 25 µg uroporphyrin and
< 125 µg coproporphyrin; n = 20); the normal ratio of co-
proporphyrin III to I isomers is approximately 75:25.
With this method the intermediate types of porphyrins
(hexacarboxy- and pentacarboxyporphyrins) are also
completely separated and detected.
Median and interquartile ranges of the laboratory
tests and of quantitative results related to the porphy-
rin excretion pattern (percentage of coproporphyrin I
in total coproporphyrins, and percentage of uropor-
phyrins in the total porphyrin excretion) were calcu-
lated for the three groups. After an F-test, Student’s 
T-test was applied to test for significant differences in
the variables between the groups II and III compared
to group I (significance was assumed for p < 0.05). Us-
ing the data of the entire group studied, linear regres-
sion was calculated between the total porphyrin excre-
tion and albumin, bilirubin, ALT, AST, AP, GGT, ferritin,
and thrombin time, and Pearson’s coefficient of corre-
lation was calculated.
Results
Normal total porphyrin excretion, including the respec-
tive porphyrinogens, was found in 59/100 of the pa-
tients (< 150 µg/g creatinine); in 31 % total porphyrin ex-
cretion was increased up to twice the normal range
(150–300 µg/g creatinine). Ten out of 100 patients had
more marked porphyrinuria of more than 300 µg/g
creatinine. Mean total porphyrin concentration calcu-
lated for all patients was 146 µg/g creatinine and me-
dian was 123 µg/g creatinine (interquartile range
76–186 µg/g creatinine, range 24–483).
Coproporphyrin excretion clearly exceeded that of
uroporphyrin in the majority of patients with porphyri-
nuria. Increased coproporphyrin excretion (> 125 µg/g
creatinine) was found in 42 patients, the median excre-
tion in all patients was 105 µg/g creatinine (interquartile
range 60–160 µg/g creatinine, mean 125 µg/g creati-
nine). The ratio of the more hydrophobic coproporphy-
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rin isomer I to isomer III was increased in the majority
of patients studied (75/100).
Increased excretion of uroporphyrin was found in 19
patients; an excretion of more than 50 µg/g creatinine
(i.e. twice the reference range) was found in only three
patients. The median uroporphyrin excretion was 15
µg/g creatinine (mean 19 µg/g creatinine). The highest
uroporphyrin excretion found was 133 µg/g creatinine;
this was the only case where the excretion of uropor-
phyrin exceeded that of coproporphyrin (32 µg/g creati-
nine). This 51 year-old female patient also was the sole
patient with a marked excretion of heptacarboxypor-
phyrin III (59 µg/g creatinine, normal < 5 µg/g) and
slightly increased pentacarboxyporphyrin excretion (9
µg/g creatinine, normal < 5 µg/g) offering the typical
patterns of chronic hepatic porphyria. The total por-
phyrin excretion, however, was only moderately ele-
vated (224 µg/g creatinine). No patient had signs of 
abnormal photosensitivity of the skin. Significant
amounts (> 5 µg/g creatinine) of hexacarboxy- or pen-
tacarboxyporphyrin were not found in the other sam-
ples studied.
Median values (with interquartile ranges) of the la-
boratory tests and of characteristics of the urinary por-
phyrin pattern among the three groups according to to-
tal porphyrin excretion are given in Table 1. Among the
ten patients of group III with marked porphyrinuria, five
had normal serum bilirubin, albumin, and plasma
thrombin time.
In the entire group a significant positive correlation
between total porphyrin excretion and serum bilirubin
was found (r = 0.46; p < 0.001), and a significant inverse
correlation with thrombin time (r = – 0.53; p < 0.001)
and albumin (r = – 0.58; p < 0.001); no significant corre-
lations were found between the total porphyrin excre-
tion and AST, ALT, AP, GGT, ferritin, and transferrin sat-
uration in the entire group. However, in the group of
patients with marked porphyrinuria, 60 % had elevated
serum ferritin and 43 % had elevated transferrin satura-
tion, in the group of patients with moderate porphy-
rinuria 29 % had increased ferritin and 21 % had 
increased transferrin saturation. Patients without 
porphyrinuria had increased ferritin in 17 % and in-
creased transferrin saturation in 10 %. No correlation
was found between HCV-RNA viral load (data not
shown) and total urinary porphyrin excretion.
In the two groups of patients with increased total uri-
nary porphyrin excretion the proportion of uroporphy-
rin to total porphyrin was lower than in normal sub-
jects.
In the control group of patients with bile duct ob-
struction (n = 18; bilirubin 79 µmol/l, range 39–376) me-
dian urinary coproporphyrin excretion was 241 µg/g
creatinine (interquartile range 144–355), with an in-
creased relative proportion of isomer I (58 %; interquar-
tile range 50–69, normal < 25 %).
Discussion
Epidemiological as well as experimental data encour-
age a reevaluation of porphyrinurias in chronic liver
disease with special respect to disease progression to
hepatocellular carcinoma. In this report we present ba-
sic epidemiological data on the porphyrin excretion in
unselected patients infected with the HCV in Germany;
these data are the prerequisite for further investiga-
tions on a possible prognostic value of porphyrin ex-
cretion in viral hepatitis.
A coproporphyrin-dominated porphyrinuria was
found in nearly half of the HCV infected patients stud-
ied; in an even higher proportion (75 %) of the patients
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Tab. 1 Liver function tests and porphyrin excretion patterns of 100 patients with chronic hepatitis C 
infection, categorised according to the total urinary porphyrin excretion.
Normal Group I Group II Group III
Total urinary < 150 < 150 150–300 > 300
porphyrin
excretion (µg/g creatine)*
N 59 31 10
Age (median, years) 46 47 52
Sex 25 f, 34 m 20 f, 11 m 2 f, 8 m
Bilirubin (µmol/l) < 17 10.3 (7.0–15.4) 12.0 (8.6–22.2) 20.5 (15.4–44.5)a
Albumin (g/l) 35–50 49 (47–50) 46 (42–48)a 39 (37–47)a
Thrombin time (%) 70–100 90 (85–95) 85 (75–90)a 70 (60–70)a
AST (U/l) 5–17 23 (16–35) 40 (24–58)a 44 (30–61)a
ALT (U/l) 5–24 38 (27–58) 58 (33–88) 42 (27–58)
GGT (U/l) 4–28 23 (12–41) 33 (21–49) 36 (25–46)
AP (U/l) 50–190 121 (100–151) 135 (110–152) 170 (156–188)a
Ferritin (ng/ml) 30–300 104 (62–209) 176 (100–367) 414 (164–531)a
% Coproporphyrin I1) 20–30 39 (28–50) 39 (21–50) 51 (40–58)
% Uroporphyrins2) 15–25 14 (10–24) 9 (7–13)a 9 (7–10)a
(median with interquartile range)
a: p < 0.05 with respect to group I
1) Percentage of total coproporphyrins
2) Percentage of total porphyrins
* Conversion factor for creatinine: 1 g/l = 8.85 mmol/l.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 19.11.13 16:59
an increased ratio of the more hydrophobic copropor-
phyrin isomer I to isomer III was found, ranging from
30 % to 58 % (normal 20 %–30 %). In contrast, a porphy-
rin pattern typical of chronic hepatic porphyria was
found in just one patient; in this case, total porphyrin
excretion was only moderately elevated. A constella-
tion that might be called “preclinical PCT” could be
found by measuring porphyrin excretion in patients
with chronic HCV infection. This condition, however, is
obviously rare in Germany.
In the entire study group, there was a weak correla-
tion of total porphyrin excretion with laboratory mark-
ers of impaired liver function; porphyrin excretion did
not correlate with serum transaminases, and GGT or
AP as markers of cholestasis. Likewise marked porphy-
rinuria (above twice the reference range) was also
found in patients with normal or only slightly impaired
liver function. The group of patients with moderate
porphyrinuria did show significant differences in liver
function tests in relation to the group without porphyri-
nuria; however, median values of serum albumin, bili-
rubin, and thrombin time in this group were within nor-
mal limits. We found altered porphyrin excretion in
HCV infection with a great interindividual variability
which was in part independent of global liver function
or disease activity. Our data show that a stratification of
HCV patients based on their porphyrin excretion is only
partially in accordance with established liver function
tests.
In a series of 56 HCV-infected patients, Cribier et al.
(26) found slightly elevated median urinary porphyrin
excretion, however, data on the distribution of the re-
spective values were not given; in addition, porphyrin
concentrations of random urine samples were not cor-
rected for urinary creatinine in this study, and copro-
porphyrin isomer distribution was not investigated. In
another cohort of 34 HCV-infected patients, O’Reilly et
al. (27) were not able to demonstrate significant urinary
porphyrin changes. Bonkovsky et al. (29) report a
rather low prevalence (15 %) of porphyrinuria in HCV-
infected patients in North America.
Several mechanisms may be responsible for secon-
dary porphyrinuria in HCV infection: impaired biliary ex-
cretion of coproporphyrins, increased porphyrin forma-
tion or a combination of both. Coproporphyrins,
especially the isomer I, are relatively hydrophobic and
thus are predominantly excreted into bile; mild choles-
tasis may lead to a coproporphyrin accumulation in the
plasma with spillover into the urine, as can be observed
in bile duct obstruction. In our series, total porphyrin ex-
cretion did not correlate with AP and GGT as the typical
laboratory markers of cholestasis, but there was a signif-
icant correlation to serum bilirubin. Thus urinary copro-
porphyrin seems indeed to be a sensitive marker of
intrahepatic cholestasis; the increased proportion of the
more hydrophobic isomer I to isomer III in urine found in
the study group with normal total urinary porphyrin ex-
cretion suggests that this ratio is an even more sensitive
indicator of early cholestasis (6). This view is in agree-
ment with the urinary porphyrin patterns found in the
control group of patients with bile duct obstruction who
had both increased urinary coproporphyrin and a raised
proportion of isomer I. Uroporphyrins are less affected
by cholestasis as they are rather hydrophilic and are pre-
dominantly excreted in the urine.
It is still speculative to assume increased whole body
total porphyrin formation (in the liver as well as in other
organ systems) in patients with porphyrinuria because
total porphyrin production can only be assessed by
summation of urinary and fecal excretion rates. Quan-
tification of overall fecal porphyrin excretion is cumber-
some in a routine setting and is difficult to standardise.
In a small series of patients (n = 8) with chronic liver 
diseases and porphyrinuria we did find a distinctly 
reduced fecal porphyrin excretion (median copropor-
phyrin 3 µg/g dried stool, interquartile range 2–7 µg/g,
compared to controls 3–24 µg/g; median percentage of
isomer I of total coproporphyrins 66 %, interquartile
range 59 %–71 %, compared to controls 66 %–74 %).
Mechanisms that might lead to increased porphyrin
synthesis in liver diseases are (i) increased heme 
turnover to meet higher cytochrome requirements or
by non-specific induction of aminolevulinic acid syn-
thase or porphobilinogen deaminase (31, 32), (ii) inef-
fective heme synthesis, possibly by decreased ferro-
chelatase activity or uroporphyrinogen decarboxylase
deficiency (33, 34) leading to precursor accumulation
(heme precursor underutilisation), (iii) increased irre-
versible oxidation of porphyrinogens by oxidative
stress, (iv) a decreased activity of heme oxigenase. 
Porphyrins, with the exception of protoporphyrin, are
notably byproducts that have escaped from the biosyn-
thetic pathway by irreversible oxidation of the corre-
sponding porphyrinogens; oxidised porphyrins are
thought to interfere with several enzymes in the meta-
bolic pathway of heme (35). Increased concentrations
of porphyrins in the liver tissue of HCV-infected patients
without PCT have been shown (34). It has to be empha-
sised, that secondary porphyrinuria is not specific for
liver disease but may also be found in neoplastic, blood
and infectious diseases (6, 36, 37).
In our series, a high proportion of patients with
marked porphyrinuria had elevated serum ferritin con-
centrations and transferrin saturation as a sign of liver
iron overload. This observation suggests an associa-
tion of iron status and secondary porphyrinopathies in
HCV infection and merits further investigation. Iron
seems to play an important pathophysiological role in
HCV infection as, for example, effects of iron depletion
on disease activity suggest (38, 39). Increased porphy-
rin excretion has been described in patients with he-
mochromatosis (40). Among PCT patients, a large pro-
portion of 44 % was found to have mutations of the
hemochromatosis gene, HFE (41). Iron has been found
to be an important cofactor in experimental chemically
induced porphyrias (21).
Whereas preclinical PCT is probably rare in HCV in-
fection, as shown in this cross-sectional study, copro-
porphyrinuria is a frequent but not obligate finding in
chronic HCV infection. This variable may be under-
stood as a screening test of altered heme metabolism
and porphyrin excretion. With respect to possible links
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between altered heme metabolism and disease pro-
gression to cirrhosis and HCC, further investigations on
the underlying pathophysiological mechanisms, in-
cluding total body porphyrin synthesis rate, and the
prognostic significance seem reasonable. In a follow-
up investigation of our series we intend to study the
course of porphyrinuria in individual patients. To clarify
the prognostic significance of urinary porphyrin excre-
tion with respect to disease progression and the occur-
rence of HCC, a larger prospective long-term study
would be required.
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